Key facts
- Notable investors include Step Holdings, Suzhou Wujiang Venture Capital, Suzhou Trust, Zhongshan Health Base Group, Xinrui Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for XinBio
- ·The full record, as it builds
Funding rounds
No funding rounds for XinBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About XinBio
Manufacturer, provider and developer of medical devices designed for cell and gene therapy. The company focuses on automated, customized and one-stop solutions for cell and gene therapy development, enabling clients with medical devices.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 80
- Website
- xinxiebio.com/
- Ownership
- Privately Held (backing)
XinBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XinBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XinBio in its N-PORT filings yet. We sweep new filings monthly.